FDA 483 - AbbVie Ireland NL. B.V. - September 10, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Abbvie Ireland NL B.V Ballytivnan in Sligo identified multiple significant deficiencies across its drug product manufacturing operations. Observations included inadequate procedures for preventing microbial contamination, insufficient visual inspection processes, and a deficient environmental monitoring program. The facility also exhibited poor maintenance, unqualified storage areas, and a lack of adherence to established SOPs, indicating a broad range of non-compliance issues that could impact product quality and sterility.
ID · 3e2598bf-a322-4d24-bb63-a1ec5157e639